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Abstract
Background: Hypertension is one of the commonest chronic diseases, yet limited data are available for related
health care utilization. Our study objective was to describe the emergency department (ED) and subsequent
hospitalization related health care utilization and charges due to hypertension in the U.S.
Methods: We used the National ED sample (NEDS) to study hypertension-related utilization and charges. Multivariable-
adjusted linear or logistic regression was used to assess hypertension-associated ED and hospitalization outcomes
(disposition, length of stay, charges), adjusted for patient demographic, comorbidity and hospital characteristics.
Results: There were 0.92, 0.97 and 1.04 million ED visits (0.71–0.77 % of all ED visits) with hypertension as the primary
diagnosis in 2009, 2010 and 2012, respectively; 23 % resulted in hospitalization. ED charges were $2.00, $2.27 and $2.86
billion, and for those hospitalized, total charges (ED plus inpatient) were $6.62, $7.09 and $7.94 billion, in 2009, 2010
and 2012, respectively. Older age (50 to 65 years), female sex, metropolitan area residence, South or West U.S. hospital
location, private insurance and the presence of congestive heart failure were each associated with higher charges for
an ED visit with hypertension as the primary diagnosis. Younger age, metropolitan residence, Medicaid insurance,
hospital location in the Northeast and co-existing diabetes, gout, coronary heart disease, chronic obstructive
pulmonary disease, hyperlipidemia and osteoarthritis were associated with higher risk, whereas male sex was
associated with lower risk of hospitalization after ED visit for hypertension. In 2012, 71.6 % of all patients hospitalized
with hypertension as the primary diagnosis were discharged home. Older age, metropolitan residence and most
comorbidities were associated with lower odds, whereas male sex, payer other than Medicare, South or West U.S.
hospital location were associated with higher odds of discharge to home.
Conclusions: Hypertension is associated with significant healthcare burden in the U.S. Future studies should assess
strategies to reduce hypertension-associated cost and health care burden.
Keywords: Emergency department, Hospitalization, Health care utilization, Charges, Hypertension, Predictors, Hospital
discharge, Predictors
Background
Hypertension is one of the commonest chronic diseases.
It affects 32.5 % of U.S. adults [1]. Hypertension is the
primary diagnosis for 38.9 million physician office visits
annually in the U.S. [1]. Hypertension and related renal dis-
ease are responsible for 27,853 deaths annually [1]. Hyper-
tension cost the U.S. approximately $49.9 billion in 2010,
$29.5 billion in direct health care expenditures and $20.4
billion in indirect costs [1, 2]. Thus, as a chronic condi-
tion, hypertension is associated with high public health
and cost burden.
Hypertension is usually accompanied by other diseases
such as heart disease, renal failure, stroke and vascular
disease [3], conditions that have significant associated
morbidity and mortality [4]. Suboptimal treatment of
hypertension may not only increase the risk of accom-
panying diseases, but also lead to higher health resource
utilization. With an increasing focus and attention on
improving the health of populations and reducing
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unnecessary health care utilization, current knowledge of
resource utilization associated with hypertension is
needed.
To our knowledge, little is known about ED and in-
patient utilization related to hypertension in the U.S. A
recent study drew attention to time-trends in ED visits
with hypertension as the primary diagnosis, and found a
4 % increase per year from 2006 to 2012 [5]. This study
focused on ED visits by age and co-existing comorbidi-
ties and examining all hypertension-related visits, with
or without hypertension as the primary diagnosis. No
analyses were performed assessing charges or the predic-
tors of ED or inpatient resource utilization after ED
visits with hypertension as the primary diagnosis [5].
Thus, knowledge gaps exist in this area, that need to be
addressed. We recently performed analyses for utilization
related to COPD and gout-related ED visits in the U.S.
and important predictors, including ED disposition, ED
and total hospital charges and predictors of ED disposition
and hospitalization outcomes [6, 7]. Using the same ap-
proach, we investigated healthcare utilization, charges and
outcomes in ED visits due to hypertension. In this study,
our aims were to: (1) describe the hypertension-related
ED and inpatient utilization and related charges in the
U.S.; and (2) assess whether patient, comorbidity or hos-
pital characteristics were predictors of ED- and inpatient
resource utilization due to hypertension.
Methods
Data source and study population
This study was performed using the discharge data
from the Nationwide Emergency Department Sample
(NEDS) [8, 9]. NEDS is the largest, publically available,
all-payer U.S. ED database that contains a 20-percent
stratified sample of ED visits from across the U.S. The
data are provided by the Agency for Healthcare Re-
search and Quality’s Healthcare Cost and Utilization
Project (HCUP) State Emergency Department Data-
bases (SEDD) and the State Inpatient Databases (SID)
[8, 9] that capture discharge information on ED visits
that do not result vs. that result in hospitalization, re-
spectively. Thirty states, including 950 U.S. hospitals,
contributed data regarding 31 million ED visits in 2012,
which were weighted to calculate the national estimates
related to 134 million ED visits in the U.S. [9].
We identified hypertension related visits in people
aged 18 and over using the International Classification
of Diseases, Common Modification (ICD-9-CM) code of
401.xx, 402.xx, 403.xx, 404.xx, and 405.xx. This ap-
proach has been shown to be valid with a positive pre-
dictive value >95 % [10, 11]. Visits are categorized as
those with 1) hypertension as the primary diagnosis
(where hypertension was listed as the first/primary diag-
nosis), and (2) hypertension as primary or secondary
diagnosis. We used the data from 2009, 2010 and 2012,
since 2011 data were not available for analyses, due to
data duplication issues.
Outcomes of interest and covariates
In this study, we examined several outcomes of interest.
These included outcomes related to ED discharge dis-
position (hospitalization, discharge to home etc.) and ED
charges. We also assessed outcomes in patients hospital-
ized with hypertension as the primary diagnosis, includ-
ing the factors associated with discharge after hospital
admission (to home vs. other; to nursing home/skilled
nursing facility vs. other), hospital stay (total duration;
hospital stay >2 days vs. ≤ 2 days) and total charges
(inpatient + ED).
NEDS includes reasons for ED visit (diagnoses and
procedures); up to 15 ICD-9-CM codes are listed in pri-
mary (first) or secondary positions (2–15). We specified
several common comorbidities in secondary position as
covariates of interest, including hyperlipidemia, coronary
heart disease (CHD), renal failure, heart failure (HF),
chronic obstructive pulmonary disease (COPD), dia-
betes, gout and osteoarthritis. Patient characteristics in-
cluding age, sex, insurance status, residence [urban vs.
rural], annual median household income estimated using
residential zip code were assessed. We also examined
hospital characteristics including geographical region, lo-
cation in metropolitan vs. non-metropolitan area, and
teaching vs. non-teaching status, as covariates.
Statistical analysis
With the exception of descriptive analyses (overall
charges, number of ED visits, hospital stay), which we
calculated for ED visits due to hypertension (hypertension
as the primary diagnosis) as well as for hypertension-
related ED visits (hypertension as the primary or second-
ary diagnosis), all other analyses were limited to visits with
hypertension as the primary diagnosis. Appropriate
weights provided by NEDS were used to obtain weighted
national estimates for 2009, 2010 and 2012.
We used the 2012 NEDS data to analyze whether pre-
specified patient and hospital factors were associated
with outcomes of interest in patients with hypertension
as the primary diagnosis for ED visits and in patients
with inpatient admission with hypertension as the pri-
mary diagnosis. We performed multivariable-adjusted lo-
gistic regression (discharge disposition from ED and
from the hospital) or linear regression (ED charges,
length of hospital stay, total charges [inpatient + ED])
using SAS version 9.3 (SAS corporation, Cary, NC,
USA). Analyses were adjusted for important confounders
and covariates including patient characteristics, comor-
bidities and hospital characteristics, as listed in the
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section above. These analyses used the actual NEDS
sample, without extrapolation to national estimates.
Sensitivity analyses were performed with log of hospital
duration of stay and total charges (ED plus inpatient),
since log variables were more normally distributed than
the original variables. We also examined factors associated
with short vs. longer hospital (≥2 days) to better under-
stand inpatient utilization due to hypertension.
Results
Clinical and demographic characteristics
Hypertension was associated with high health care
utilization in the ED in the U.S., which also seemed to
have increased over the study period. The number of ED
visits for hypertension as the primary diagnosis were
0.92 million in 2009, 0.97 in 2010 and 1.04 million in
2012 (Table 1), a 13 % increase in 4 years. The mean age
for patients with ED visit with hypertension in 2012 was
59 years, 57 % were female and 15 % were in the highest
income quartile (≥$63,000) (Table 1). In 2012, Medicare
was the primary payer for 43 %, and almost half of all
ED visits for hypertension occurred in hospitals located
in the Southern U.S, with only 16 % each in Northeastern
and Western U.S and 20 % in the Midwest. Patient char-
acteristics were similar across study years including sex,
residence, the primary payer, hospital region and teaching
status etc. (Table 1).
ED and inpatient charges for Hypertension-visits (primary)
and hypertension-related (primary or secondary) visits
ED visits with hypertension as the primary diagnosis
constituted 0.71–0.77 % of all ED visits. The proportions
Table 1 Emergency department (ED) visits for hypertension as the primary diagnosis in year 2009, 2010 and 2012 NEDS databasea
2009 NEDS 2010 NEDS 2012 NEDS
ED visits 920,984 (0.71) 972,631 (0.75) 1,041,223 (0.77)
Age, in years
Mean (SE) 58.64 (0.23) 58.43 (0.22) 59.17 (0.22)
Median (IQR) 56.96 (45.44, 71.73) 56.79 (45.35, 71.28) 57.95 (46.29, 71.98)
Sex
Female 530,143 (57.62) 558,253 (57.40) 595,212 (57.17)
Patient location (residence)
Micropolitan/not metro 169,247 (18.51) 175,858 (18.19) 184,852 (17.84)
Metropolitan (large or small) 744,925 (81.49) 791,005 (81.81) 851,485 (82.16)
Median house hold income
1st quartile (< $38,999) 340,766 (37.96) 368,468 (38.80) 389,354 (38.19)
2nd quartile ($39,000 to $47,999) 250,997 (27.96) 252,070 (26.55) 255,324 (25.04)
3rd quartile ($48,000 to $62999) 179,959 (20.05) 186,460 (19.64) 219,568 (21.53)
4th quartile ($63,000 or more) 125,880(14.02) 142,564 (15.01) 155,369 (15.24)
Primary payer
Medicare 370,933 (40.37) 391,925 (40.41) 443,993 (42.69)
Medicaid 106,282 (11.57) 119,606 (12.33) 138,606 (13.33)
Private insurance 244,669 (26.63) 247,195 (25.49) 229,988 (22.12)
Self-pay/No charge 167,334 (18.32) 182,153 (18.78) 189,031 (18.18)
Other 28,560 (3.11) 29,001 (2.99) 38,337 (3.69)
Hospital Region
Northeast 148,302 (16.10) 168,618(17.34) 168,303 (16.16)
Midwest 183,785 (19.96) 207,731 (21.36) 219,784 (21.11)
South 448,654 (48.71) 447,419 (46.00) 490,154 (47.07)
West 140,244 (15.23) 148,863 (15.31) 162,982 (15.65)
Teaching status of hospital
Metropolitan non -teaching or non-metro 555,998 (60.37) 557,804 (57.35) 576,146 (55.33)
Metropolitan teaching 364,986 (39.63) 414,827 (42.65) 465,077 (44.67)
aData shown are n (%), unless specified otherwise
SE standard error, IQR inter-quartile range
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of all ED visits that were due to hypertension as the pri-
mary diagnosis were stable across the study years of
2009, 2010 and 2012 at 0.71, 0.75 and 0.77 %; however,
the respective ED charges increased and were $2.00,
$2.27 and $2.86 billion, respectively (Table 2). We also
noted a similar increase in the total charges for ED and
inpatient services in patients who were hospitalized with
hypertension as their primary diagnosis at $6.62, $7.09
and $7.94 billion, respectively (Table 2).
For the three study years, 2009, 2010 and 2012, of the
ED-visits for hypertension as the primary diagnosis, 26,
25 and 23 % were hospitalized, respectively (Additional
file 1). Respective mean ED charges for visits with hyper-
tension as the primary diagnosis were $2,169, $2,334
and $2,747 per ED visit. Respective mean total charges
(ED plus inpatient) in those hospitalized with hyperten-
sion as the primary diagnosis were $27,619, $29,177 and
$32,761. The mean length of hospital stay was 4.1, 4.0
and 4.0 days, respectively (Additional file 1).
Total ED and inpatient charges with hypertension
diagnosis in any position (primary or secondary), i.e.
hypertension-related visits, were $406 billion in 2012,
higher than the $341 billion in 2009 (Table 2).
ED charges and discharge disposition for visits due to
hypertension as the primary diagnosis
We used multivariable-adjusted linear regression adjust-
ing for patient demographic, comorbidities and hospital
characteristics to assess factors associated with higher
charges for an ED visit with hypertension as the primary
diagnosis. We found that age <50 years, female sex, resi-
dence in metropolitan area, private insurance, presence
of HF and hospital location in South or West U.S. loca-
tion were each associated with higher charges for an ED
visit with hypertension as the primary diagnosis (Add-
itional file 2).
Multivariable-adjusted logistic regression showed that
younger age, metropolitan residence, Medicaid insurance
and hospital location in the Northeast were associated
with higher risk of hospitalization after ED visit for
hypertension as the primary diagnosis (Table 3); male
sex was associated with lower risk of hospitalization for
hypertension. Patients with co-existing diabetes, gout,
CHD, COPD, hyperlipidemia, renal failure, HF and
osteoarthritis had a significantly higher adjusted odds of
being admitted compared to patients without each of
these conditions (Table 3). Unadjusted estimates for pa-
tients with ED-visit with hypertension as the primary
diagnosis who were and were not subsequently admitted
to the hospital are shown in Additional file 3.
Hospitalization disposition and predictors for
Hypertension-visits (primary)
In 2009, 2010 and 2012, 73.6 %, 73.1 % and 71.6 % of all
patients hospitalized with hypertension as the primary
diagnosis were discharged home (Additional file 4),
respectively. Discharge disposition to other settings after
hospitalization for hypertension did not vary by the
study year.
Table 2 Descriptives for the main ED visit-related outcomes with hypertension diagnosis
2009 2010 2012
Hypertension visits (hypertension as the primary diagnosis)
All Hypertension ED visits with hypertension as primary
diagnosis weighted n (% of total ED visits))
920,984 (0.71) 972,631 (0.75) 1,041,223 (0.77)
Total ED charges ($) 1,997,899,801 2,269,712,249 2,859,937,626
All Hypertension ED visits (not admitted to the same hospital)
with hypertension as primary diagnosis
681,136 725,960 798,826
Total ED charges ($) 1,618,467,684 1,836,308,560 2,359,979,640
All Hypertension inpatient admissions with hypertension as
primary diagnosis for those with ED visits
239,847 243,071 242,397
Total inpatient charges ($) 5,770,718,820 6,295,295,829 7,051,813,524
Duration of hospital stay, in days 4.13 (0.05) 4.02 (0.05) 3.98 (0.05)
Total charges for ED and inpatient services ($) 6,624,334,293 7,092,082,567 7,941,168,117
Hypertension-related visits (hypertension as the primary or
secondary diagnosis)
All Hypertension inpatient admissions with hypertension in
any position for those with ED visits
10,257,840 10,504,104 10,333,391
Total inpatient charges ($) 307,283,855,040 328,431,819,768 360,997,014,585
Duration of hospital stay, in days mean (SE) 4.93 (0.04) 4.81 (0.03) 4.72 (0.04)
Total charges for ED and inpatient services ($) 340,703,897,760 364,460,896,488 406,133,266,473
SE standard error
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Multivariable-adjusted analyses showed that older age,
metropolitan residence, CHD, renal failure, HF, diabetes,
COPD and osteoarthritis were associated with lower
odds, whereas male sex, payer other than Medicare,
South or West U.S. hospital location, hyperlipidemia and
gout were associated with higher odds of discharge to
home (Table 4).
Length of Hospital Stay and total charges for
Hypertension-visits (primary)
Multivariable-adjusted linear regression showed that
older age categories (50- <65, 65- <80 and ≥80, com-
pared to age <50 years), metropolitan patient residence,
metropolitan teaching hospital, Medicaid as primary
payer and several comorbidities including renal failure,
HF, diabetes, and COPD were associated with longer
hospital stay for hypertension (Table 5). On the other
hand, hyperlipidemia, osteoarthritis, private insurance
and hospital location other than Northeast were associ-
ated with shorter hospital stay for patients admitted to
the hospital with hypertension as the primary diagnosis
(Table 5).
In multivariable-adjusted analyses, older age, median
household income in the highest quartile, metropolitan
location and most comorbidities including CHD, renal
failure, gout, HF, and COPD were associated higher total
(ED + inpatient) hospital charges for hypertension hospi-
talizations (Table 6). Uninsured primary payer, Midwest
U.S. hospital location, hyperlipidemia and osteoarthritis
were associated with lower hospital charges for hyper-
tension hospitalizations (Table 6).
We performed several sensitivity analyses to examine
whether our findings were robust or not. Sensitivity ana-
lyses examining the log of hospital stay (Additional file
5), hospital stay dichotomized at 2 days (Additional file
6), or the log of total hospital charges (Additional file 7)
showed similar results as the analyses above, and sup-
ported the robustness of our findings.
Discussion
Our study provided contemporary national estimates of
ED and inpatient utilization and charges for patients
with hypertension as the primary diagnosis. We found
Table 3 Predictors of hospital admission among patients








50- <65 1.33 (1.28, 1.38)*** 0.90 (0.86, 0.94)***
65- <80 1.60 (1.52, 1.68)*** 0.74 (0.69, 0.79)***
≥80 2.26 (2.12, 2.40)*** 0.91 (0.83, 0.98)*
Gender
Female Ref Ref
Male 1.19 (1.15, 1.23)*** 0.93 (0.89, 0.97)**
Median household income
1st quartile (< $38,999) Ref Ref
2nd quartile
($39,000 to $47,999)
0.95 (0.88, 1.02) 0.96 (0.88, 1.04)
3rd quartile
($48,000 to $62999)
1.00 (0.91, 1.10) 0.95 (0.85, 1.06)
4th quartile
($63,000 or more)
1.11 (1.00, 1.25) 0.95 (0.84, 1.09)
Primary payer
Medicare (ref) Ref Ref
Medicaid 0.79 (0.74, 0.85)*** 1.14 (1.02, 1.27)
Private insurance 0.45 (0.43, 0.47)*** 0.99 (0.92, 1.07)
Self-pay/No charge 0.36 (0.33, 0.40)*** 0.96 (0.87, 1.06)
Other 0.56 (0.47, 0.66)*** 1.21 (1.01, 1.44)*
Patient location (residence)
Micropolitan/not metro Ref Ref
Metro (large or small) 1.84 (1.65, 2.04)*** 1.68 (1.50, 1.90)***
Hospital Region
Northeast Ref Ref
Midwest 0.75 (0.62, 0.91)* 0.62 (0.51, 0.75)***
South 0.75 (0.63, 0.88)* 0.67 (0.54, 0.81)***
West 0.73 (0.61, 0.88)*** 0.51 (0.40, 0.65)***




Metropolitan teaching 1.37 (1.22, 1.54)*** 1.04 (0.89, 1.21)
Comorbidities
CHD (ref: no) 7.27 (6.84, 7.72)*** 2.80 (2.64, 2.97)***
Hyperlipidemia (ref: no) 4.90 (4.55, 5.26)*** 3.27 (3.03, 3.54)***
Renal failure (ref: no) 14.08 (12.83, 15.46)*** 7.52 (6.86, 8.25)***
Heart Failure (ref: no) 22.38 (20.58, 24.34)*** 8.55 (7.86, 9.30)***
Gout (ref: no) 5.52 (4.96, 6.15)*** 1.86 (1.60, 2.18)***
Table 3 Predictors of hospital admission among patients
presenting to ED with hypertension as the primary diagnosis
(Continued)
Diabetes (ref: no) 3.57 (3.42, 3.73)*** 1.51 (1.44, 1.58)***
COPD (ref: no) 5.62 (5.24, 6.02)*** 2.09 (1.94, 2.24)***
Osteoarthritis (ref: no) 5.64 (4.92, 6.45) 3.76 (3.18, 4.44)***
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease;
OR, odds ratio; CI, confidence interval
aOdds ratio from the logistic regression
*p-value <0.05; **p-value <0.01; ***p-value <0.001; Significant odds ratios are
in bold
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that hypertension was the primary diagnosis (i.e., main
reason) for over 1 million ED visits in 2012, which were
roughly 0.7–0.8 % of all ED visits. Of these ED visits in
2012, 23 % resulted in hospitalization. We also examined
the factors associated with health resource utilization
and charges for ED and inpatient visits due to hyperten-
sion, i.e. with hypertension as the primary diagnosis.
We noted a 13 % increase in ED utilization due to
hypertension in 4-years in contrast to decreasing
utilization for hypertension reported recently in a Can-
adian study [12]. Differences in study findings may be
due to differences in health care systems (multiple in-
surer system vs. single-payer Government system), coun-
try setting (U.S. vs. Canada) and the study time period
(2009-2012 vs. 1997-2004). It is reassuring that our esti-
mates of 13 % increase over 4 years (i.e. 3–4 % per year)
and the overall number of ED visits almost replicate the
4 % annual increase reported in the previous 6-year
NEDS study of ED visits with a primary diagnosis of
hypertension, with slight difference due to inclusion of
an additional code 437.2 in the earlier study [5].
Our study defines the public health burden and health
care burden of hypertension in the emergency depart-
ments and hospitals in the U.S. To our knowledge, there
is a lack of nationally representative studies assessing the
burden of hypertension in the U.S., except a recent de-
scriptive study [5]. These were ED visits with a primary
diagnosis of hypertension and/or uncontrolled or un-
treated hypertension with other non-specific associated
symptoms such as headache, dizziness, pedal edema,
worsening of heart failure etc. These visits are unlikely
to be due to stroke, myocardial infarction (MI) in the
setting of hypertension urgencies or emergencies [13],
since visits with these acute conditions would likely have
stroke or MI as the primary diagnoses, not hypertension.
We found that of the ED-visits with hypertension as
the primary diagnosis, 23 % resulted in hospitalizations.
This admission rate was higher than that for gout-
related ED visits at 7.7 % [7] and lower than the 49 %
for COPD-related ED visits in the U.S. [6], analyzed for
the same years using similar methodology and analyses,
as this study. We planned these analyses a priori to be
similar to our previous analyses of patients with COPD
or gout to allow across-disease comparability of
Table 4 Predictors of Discharge to home among patients who
had a hospital admission after presenting to ED with








50- <65 0.62 (0.58, 0.68)*** 0.74 (0.68, 0.81)***
65- <80 0.28 (0.25, 0.30)*** 0.48 (0.43, 0.53)***
≥80 0.12 (0.11, 0.13)*** 0.21 (0.18, 0.23)***
Gender
Female Ref Ref
Male 1.28 (1.22, 1.34)*** 1.06 (1.00, 1.11)*
Median house hold income
1st quartile (< $38,999) Ref Ref
2nd quartile ($39,000 to
$47,999)
0.96 (0.89, 1.04) 1.05 (0.97, 1.14)
3rd quartile ($48,000 to
$62999)
0.89 (0.80, 0.98)* 1.05 (0.95, 1.16)
4th quartile ($63,000 or
more)
0.70 (0.64, 0.77)*** 1.00 (0.90, 1.10)
Primary payer
Medicare Ref Ref
Medicaid 2.67 (2.46, 2.90)*** 1.39 (1.25, 1.55)***
Private insurance 4.29 (3.93, 4.68)*** 2.07 (1.88, 2.27)***
Self-pay/No charge 7.23 (6.53, 8.01)*** 2.71 (2.35, 3.12)***
Other 4.89 (3.92, 6.10)*** 2.20 (1.76, 2.74)***
Patient location (residence)
Micropolitan/not metro Ref Ref
Metropolitan (large or small) 0.97 (0.87, 1.09) 0.89 (0.80, 0.99)*
Hospital Region
Northeast Ref Ref
Midwest 1.27 (1.08, 1.50)** 1.10 (0.94, 1.29)
South 1.56 (1.40, 1.74)*** 1.45 (1.28, 1.64)***
West 1.64 (1.41, 1.91)*** 1.80 (1.55, 2.09)***




Metropolitan teaching 1.15 (1.02, 1.29)* 1.15 (1.04, 1.28)
Comorbidities
CHD (ref: no) 0.59 (0.56, 0.63)*** 0.98 (0.93, 1.03)
Hyperlipidemia (ref: no) 1.05 (1.00, 1.10)* 1.28 (1.22, 1.35)***
Renal failure (ref: no) 0.52 (0.48, 0.55)*** 0.75 (0.71, 0.80)***
Heart Failure (ref: no) 0.36 (0.34, 0.39)*** 0.62 (0.59, 0.66)***
Gout (ref: no) 0.79 (0.73, 0.87)*** 1.14 (1.03, 1.26)**
Diabetes (ref: no) 0.75 (0.71, 0.78)*** 0.82 (0.78, 0.86)***
COPD (ref: no) 0.50 (0.47, 0.54)*** 0.81 (0.75, 0.87)***
Table 4 Predictors of Discharge to home among patients who
had a hospital admission after presenting to ED with
hypertension as the primary diagnosis (Continued)
Osteoarthritis (ref: no) 0.62 (0.58, 0.67)*** 0.94 (0.86, 1.02)
Length of stay, in days 0.84 (0.83, 0.86)*** 0.88 (0.87, 0.89)***
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease;
OR, odds ratio; CI, confidence interval
aOdds ratio from the logistic regression
*p-value <0.05; **p-value <0.01; ***p-value <0.001; Significant odds ratios are
in bold
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estimates and predictors of national U.S. healthcare
utilization data. Of those hospitalized, 71.6 % were dis-
charged home. The mean 2012 ED and inpatient charges
were $2,747 and $32,761 per visit respectively and the
mean length of hospital stay was 4.0 days. Total 2012
charges for ED and inpatient visits with hypertension as
the primary diagnosis were $2.86 billion and $7.94 bil-
lion, respectively. These charges are comparable to total
charges nationally for diabetic foot at $8.78 billion in
2010 [14], higher than changes for constipation at $1.62
billion [15], but lower than those for COPD at $14.2
billion in 2012 [6]. The mean ED visit charges of $2,747
for hypertension is slightly higher than that ED visits for
diabetic foot at $2,324 [14] and for constipation at
$2,306 [15], and similar to those for COPD [6].
Total ED and inpatient charges with hypertension
diagnosis in any position (primary or secondary) were
$406 billion in 2012. Concomitant hypertension in pa-
tients with diabetes is associated with higher healthcare
utilization [16, 17]. Thus, the cost and morbidity burden
of hypertension in the U.S. is quite significant. As a dis-
ease for which multiple treatment options are available,
at least significant proportion of charges and burden
may be preventable, by increasing patient awareness and
knowledge, optimal medication adherence and access to
outpatient clinics. These interventions may also further
reduce the risk of associated complications, such as
myocardial infarction, stroke etc. [3, 18].
We noted regional differences in health care utilization
for hypertension regarding the risk of hospitalization,
length of hospital stay, proportion discharged to home
etc. Regional differences can be due to multiple reasons
including due to regional differences in income, payment
by insurers due to adjustment for cost-of-living and dif-
ferences in health status [19]; health care intensity varies
by region in the U.S. [20].
Table 5 Predictors of duration of hospital stay among patients
with hypertension who were admitted to the hospital after








50- <65 0.49 (0.37, 0.61)*** 0.47 (0.35,0.59)***
65- <80 1.00 (0.86, 1.15)*** 0.83 (0.66,1.01)***
≥80 1.13 (0.97, 1.29)*** 0.89 (0.72,1.05)***
Gender
Female Ref Ref
Male 0.17 (0.08, 0.26)** −0.03 (−0.12,0.06)











0.07 (−0.10, 0.25) 0.06 (−0.10, 0.23)
4th quartile
($63,000 or more)
0.27 (0.07, 0.48)** 0.09 (−0.08, 0.27)
Primary payer
Medicare (ref) Ref Ref
Medicaid −0.10 (−0.27, 0.08) 0.47 (0.28, 0.66)***
Private insurance −1.05 (−1.17, −0.93)*** −0.14 (−0.27, 0.00)*
Self-pay/No
charge
−1.32 (−1.50, −1.14)*** −0.19 (−0.40, 0.03)







0.36 (0.15, 0.56)** 0.17 (0.02, 0.32)*
Hospital Region
Northeast Ref Ref
Midwest −0.85 (−1.17, −0.53)*** −0.88 (−1.16, −0.60)***
South −0.58 (−0.87, −0.29)** −0.56 (−0.81, −0.31)***
West −0.58 (−0.89, −0.26)** −0.85 (−1.13, −0.56)***







0.24 (0.05, 0.44)* 0.19 (0.02, 0.35)*
Comorbidities
CHD (ref: no) 0.54 (0.44, 0.65)*** −0.05 (−0.14, 0.05)
Hyperlipidemia
(ref: no)
−0.51 (−0.60, −0.41)*** −0.59 (−0.68, −0.50)***
Table 5 Predictors of duration of hospital stay among patients
with hypertension who were admitted to the hospital after




2.10 (1.95, 2.25)*** 1.63 (1.48, 1.78)***
Heart Failure
(ref: no)
2.07 (1.94, 2.20)*** 1.53 (1.41, 1.65)***
Gout (ref: no) −0.48 (−0.66, −0.31)*** 0.13 (−0.05, 0.30)
Diabetes (ref: no) 0.57 (0.47, 0.67)*** 0.11 (0.02, 0.21)*
COPD (ref: no) 1.01 (0.87, 1.15)*** 0.29 (0.16, 0.42)***
Osteoarthritis
(ref: no)
−0.16 (−0.32, −0.01)* −0.16 (−0.30, −0.02)*
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease
abeta-estimate from linear regression
*p-value <0.05; **p-value <0.01; ***p-value <0.001; Significant estimates are
in bold
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Table 6 Predictors of total hospital charges (inpatient + ED charges) among patients with hypertension hospitalized after presenting
to ED with hypertension as the primary diagnosis
Univariate Multivariable-adjusted
B-estimatea (95 % CI) P-value B-estimatea (95 % CI) P-value
Age
<50 Ref Ref
50- <65 4099.5 (2790.9, 5408.1) <0.0001 3478.3 (2007.5, 4949.1) <0.0001
65- <80 7602.0 (5920.2, 9283.9) <0.0001 4916.7 (3322.1, 6511.3) <0.0001
≥80 5465.2 (3421.7, 7508.6) <0.0001 1419.5 (−346.3, 3185.3) 0.1149
Gender
Female (ref) Ref Ref
Male 2634.0 (1658.1, 3609.9) <0.0001 273.2 (−603.8, 1150.2) 0.5410
Median household income
1st quartile (< $38,999) Ref Ref
2nd quartile ($39,000 to $47,999) 2807.9 (573.2, 5042.6) 0.0139 1551.8 (−519.5, 3623.2) 0.1418
3rd quartile ($48,000 to $62999) 4816.3 (1994.3, 7638.3) 0.0008 2010.2 (−454.3, 4474.7) 0.1097
4th quartile ($63,000 or more) 8879.6 (4721.0, 13038.2) <0.0001 4122.0 (447.4, 7796.7) 0.0280
Primary payer
Medicare Ref Ref
Medicaid 109.4 (−2624.6, 2843.44) 0.9374 1633.7 (−1032.0, 4299.4) 0.2293
Private insurance −5403.9 (−6842.8, −3965.1) <0.0001 −343.7 (−1752.1, 1064.8) 0.6320
Self-pay/No charge −9279.1 (−11307.1, −7251.05) <0.0001 −2197.7 (−4074.3, −321.0) 0.0218
Other −5871.1 (−9599.0, −2143.1) 0.0021 −3775.8 (−6842.5, −709.2) 0.0159
Patient residence
Micropolitan/not metro Ref Ref
Metropolitan (large or small) 10950.6 (8508.3, 13392.9) <0.0001 8651.8 (6361.1, 10942.5) <0.0001
Hospital Region
Northeast Ref Ref
Midwest −9957.2 (−16070.1, −3844.23) 0.0014 −9936.6 (−15814.5, −4058.8) 0.0010
South −5883.6 (−11886.2, 119.0) 0.0547 −5384.8 (−11298.4, 528.80) 0.0742
West 14494.2 (7118.5, 21869.9) 0.0001 11992.9 (5047.4, 18938.3) 0.0007
Teaching status of hospital
Metropolitan non –teaching or non-metro Ref Ref
Metropolitan teaching −1801.1 (−5304.5, 1702.3) 0.3131 −1094.6 (−4385.9, 2196.7) 0.5140
Comorbidities
CHD (ref: no) 5309.5 (3931.5, 6687.6) <0.0001 1403.8 (186.8, 2620.8) 0.0238
Hyperlipidemia (ref: no) −3780.9 (−4842.8, −2719.0) <0.0001 −3947.7 (−4872.1, −3023.3) <0.0001
Renal failure (ref: no) 15161.4 (13324.7, 16998.1) <0.0001 11217.3 (9614.5, 12820.1) <0.0001
Heart Failure (ref: no) 16095.3 (14106.3,18084.2) <0.0001 11954.3 (10060.2, 13848.5) <0.0001
Gout (ref: no) −2037.1 (−3945.0, −129.2) 0.0364 2219.1 (520.7, 3917.6) 0.0105
Diabetes (ref: no) 3422.1 (2450.1, 4394.2) <0.0001 −661.5 (−1662.0, 338.9) 0.1946
COPD (ref: no) 7870.4 (5955.5, 9785.3) <0.0001 2955.0 (1137.8, 4772.2) 0.0015
Osteoarthritis (ref: no) −4400.6 (−6279.1, −2522.1) <0.0001 −2858.6 (−4473.5, −1243.7) 0.0005
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; Significant beta coefficients are in bold
aBeta-estimate from linear regression
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Our study identified several risk factors for higher ED
charges with hypertension as the primary diagnosis. This
fills a knowledge gap. Younger age, female sex, residence
in metropolitan area, hospital location in South or West
U.S. location, private insurance and the presence of HF
were each associated with higher charges for an ED
visit. Similarly, younger age, female sex, metropolitan
residence, Medicaid insurance and hospital location in
the Northeast, and co-existing diabetes, gout, CHD,
COPD, hyperlipidemia and osteoarthritis were associ-
ated with a higher risk of hospitalization with hyperten-
sion as the primary diagnosis. Most comorbidities were
associated with 1.5–3.3 fold higher risk of inpatient ad-
mission with hypertension as the primary diagnosis ex-
cept renal failure and HF, which were associated with
much higher odds of 7.5 and 8.6, respectively. Thus, we
identified risk factors associated with higher rates of
hospitalization (significantly more expensive than an
ED visit alone) and higher charges. This paves the way
for future studies that should examine whether
optimization of associated comorbidities and/or recog-
nition of high-risk patients with hypertension (based on
socio-demographic characteristics) for frequent out-
patient follow-up and implementation of special pro-
grams to improve access to outpatient health care
teams can help reduce burden and costs associated with
hypertension-associated ED and inpatient use. Our
study further extends the recent finding that patients
with hypertension with concomitant comorbidities are
more likely to hospitalized compared to patients with-
out comorbidities [12].
Another important observation from our study was that
11 % patients with inpatient utilization due to hyperten-
sion were discharged to skilled nursing/intermediate facil-
ities and 13 % to home health care while 73 % were
discharged to home. Older age, metropolitan residence
and most comorbidities (except hyperlipidemia and gout)
were associated with lower odds, whereas male sex, payer
other than Medicare and South or West U.S. hospital lo-
cation were associated with higher odds of discharge to
home. The next step in this research should be to identify
potential targets for intervention studies with an aim to
reduce health care utilization and costs due to hyperten-
sion. It also remains to be seen whether optimization of
key comorbidities we identified as risk factors can reduce
morbidity and associated charges/costs.
We found that older age, metropolitan patient resi-
dence, metropolitan teaching hospital and Medicaid as
primary payer and most comorbidities except hyperlipid-
emia and osteoarthritis were associated with longer stay
whereas private insurance, hospital location other than
Northeast were associated with shorter hospital stay.
Similarly, older age, median household income in the
highest quartile, metropolitan location and most
comorbidities except hyperlipidemia and osteoarthritis
were associated higher inpatient hospital charges. Unin-
sured primary payer and Midwest U.S. hospital location
were associated with lower hospital charges.
Our findings must be interpreted considering study
limitations. NEDS contains event-level data but not
unique identifiers so that individuals may be repre-
sented by multiple visits in any given year. We were not
able to examine readmission rates due to the lack of
this information in NEDS. Study findings are likely not
generalizable to other countries due to differences in
health care settings. We suspect residual confounding
due to the lack of availability of details regarding opti-
mal vs. suboptimal control of hypertension [21] and the
rate of adherence with anti-hypertensive medication
[22], both of which are important factors for healthcare
utilization. It is far more likely that these factors are
causes/mediators of increased ED and inpatient
utilization, rather than confounders. In addition, we are
unaware of any data indicating that associations we
noted are mediated through these factors. Therefore,
even though the estimates may be possibly over- or
under-estimates, the confounding bias is unclear/un-
known. Outpatient utilization data were not available,
and a study of hypertension associated complications
such as stroke, myocardial infarction, renal failure etc.
were beyond the scope of this study. Availability of only
three years of data for our analyses did not allow us to
have a very comprehensive look at time-trends; data
from more years would have made this analysis more
informative. However, some trends in cost very evident
in this short time-period, as reported. Several regional
differences were noted in various outcomes, but de-
tailed analyses by region were outside the scope of this
paper, and limited resources prevented us from doing
these analyses.
Study strengths include the use of the largest ED and
hospitalization data in the U.S. that is representative and
generalizable to the U.S. population, inclusion of several
important outcomes, and important covariates as potential
predictors, and examination of data across several years.
Conclusions
In summary, this contemporary study using national
U.S. data provides a comprehensive assessment of ED
and inpatient health care burden and charges due to
hypertension in the U.S. The burden of hypertension is
substantial and slowly increasing. We identified several
important factors associated both with ED and inpatient
charges for hypertension as well as disposition from ED
and inpatient settings. Several of these factors may be
modifiable and present potential targets for future inter-
ventions to reduce health care utilization and cost due
to hypertension.
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